@FiercePharma: Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. Yesterday's story | Follow @FiercePharma
@EricPFierce: Finally, something that Teva can crow about. Treanda gets orphan status, extending its exclusivity. News | Follow @EricPFierce
@CarlyHFierce: Our annual Top Women in Biotech report is live! Special report | Follow @CarlyHFierce
> Several government agencies in India are fighting over the proposition of capping foreign ownership of drug companies there. Story
> U.S. hedge fund Elliott International, known for taking stakes in companies about to be bought in an effort to force higher prices, has increased its stake to more than 25% in the German pharmaceutical retailer Celesio, which McKesson ($MCK) has offered to buy in an $8.4 billion deal. Story (sub. req.)
> South Korea's CRO SillaJen will buy San Francisco, CA-based cancer company Jennerex Biotherapeutics for up to $150 million in cash and milestones. Story
> Princeton has little to worry about legally by allowing the use of the use of Novartis ($NVS) meningitis vaccine Bexsero for an outbreak there. Story
> Pharmacy chain CVS Caremark ($CVS) will pay $2.1 billion to buy home infusion specialist Coram from Apria Healthcare Group. Story (sub. req.)
> AstraZeneca ($AZN) has named an architect to design its new global R&D center and corporate headquarters in Cambridge, England, that will house 2,000 employees. Report
@FierceMedDev: 23andMe digs in as FDA wants test off the market. Story | Follow @FierceMedDev
@MarkHFierce: Please check out our latest issue of FierceDiagnostics, with lots of great industry news. Issue | Follow @MarkHFierce
> Cardiovascular Systems bags $102M for artery-clearing Diamondback 360 device. Story
> Swiss team's anti-obesity hormone implant poses Lap-Band challenge. News
> Medtronic's Ishrak: Day-to-day business takes precedence over device tax angst. More
Biotech News
@FierceBiotech: What would a Teva buyout mean for its R&D operation? Story | Follow @FierceBiotech
@JohnCFierce: GlaxoSmithKline dispatching R&D teams to new satellites in Cambridge, San Diego. Story | Follow @JohnCFierce
@DamianFierce: Sorin's expecting as much as 10% annual growth by 2018. Story | Follow @DamianFierce
@EmilyMFierce: Malaria cases soar in former rebel stronghold of Rutshuru, DRC. More | Follow @EmilyMFierce
> Korean CRO grabs failed cancer vaccine in $150M-max Jennerex buyout. Story
> Theraclone reels as feds deny funding for flu antibody. News
> Galapagos reaps $46M payday as GSK preps PhII study. Item
Drug Delivery News
> Study: Natural nanomaterials could support biodegradable drug delivery. Story
> Alnylam pockets $7M from Genzyme as RNAi program hums along. Article
> Aptar Pharma readies auto-injectable drug delivery tech. Report
> Focal Therapeutics' 3-D tissue marker for targeted cancer therapy reaches milestone. Story
> Arrowhead submits PhIIa application for hep B RNAi candidate. Article
> Supramolecular gel scaffold may support bone drug delivery. Item
Diagnostics News
> Veracyte boosts Dx revenue as CEO Anderson celebrates successful IPO. Story
> Canadian team relies on synchrotron to develop better prostate cancer Dx. Article
> In 23andMe's tussle with the FDA, 'diagnostic' is a contentious word. Story
> Oxford Immunotec, a TB Dx developer, performs well in its Nasdaq debut. Report
> Myriad ups companion Dx focus with BioMarin cancer drug collaboration. News
> BioMérieux team touts development of quicker sepsis Dx approach. Item
Biomarkers News
> Blood biomarker points to post-concussion cognitive problems. Report
> Regulus snags milestone in MS biomarker deal with Biogen. News
> Protein C4d linked to higher mortality rates in lung cancer patients. Story
> Women who test negative for BRCA mutation may still have higher breast cancer risk. Article
> Chemical fingerprint points to a likely biomarker for 'fast' form of Parkinson's. More
> Gentris opens biomarker shop in Shanghai. Item
Vaccines News
> FDA approves GSK's adjuvanted bird flu vaccine for stockpile. Report
> Novartis struggling to find vaccine acquisition targets for $5B war chest. Article
> Ranbaxy reportedly ready to sell vaccine unit. More
> Sanofi hunting for bolt-on vaccine deals. Story
> Value of Pentagon-backed vaccine plant questioned. News
> GAVI adds support for inactivated polio vaccine. Item
And Finally... Oops, not another government website issue. The FDA is reopening the comment period for the "Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1)" because technical issues for 10 days earlier this month kept some people from commenting. Announcement